Medications

Ranbaxy taking 'stringent steps' to end US FDA ban

India's biggest drugmaker by sales, Ranbaxy Laboratories, has assured shareholders it is taking "stringent steps" to resolve a US ban on imports of medicines made at its newly renovated showcase plant.

Other

Novo Nordisk US shares skid on drug review setback (Update)

Shares of Novo Nordisk tumbled Monday after the Danish drugmaker said U.S. regulators need a new study before they can finish their review of two diabetes treatments, a development that could delay approval for several years.

page 2 from 2